Literature DB >> 17015488

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.

Balázs Sarkadi1, László Homolya, Gergely Szakács, András Váradi.   

Abstract

In this review we give an overview of the physiological functions of a group of ATP binding cassette (ABC) transporter proteins, which were discovered, and still referred to, as multidrug resistance (MDR) transporters. Although they indeed play an important role in cancer drug resistance, their major physiological function is to provide general protection against hydrophobic xenobiotics. With a highly conserved structure, membrane topology, and mechanism of action, these essential transporters are preserved throughout all living systems, from bacteria to human. We describe the general structural and mechanistic features of the human MDR-ABC transporters and introduce some of the basic methods that can be applied for the analysis of their expression, function, regulation, and modulation. We treat in detail the biochemistry, cell biology, and physiology of the ABCB1 (MDR1/P-glycoprotein) and the ABCG2 (MXR/BCRP) proteins and describe emerging information related to additional ABCB- and ABCG-type transporters with a potential role in drug and xenobiotic resistance. Throughout this review we demonstrate and emphasize the general network characteristics of the MDR-ABC transporters, functioning at the cellular and physiological tissue barriers. In addition, we suggest that multidrug transporters are essential parts of an innate defense system, the "chemoimmunity" network, which has a number of features reminiscent of classical immunology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015488     DOI: 10.1152/physrev.00037.2005

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  221 in total

1.  Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.

Authors:  Ke-Jun Liu; Jie-Hua He; Xiao-Dong Su; Hong-May Sim; Jing-Dun Xie; Xing-Gui Chen; Fang Wang; Yong-Ju Liang; Satyakam Singh; Kamlesh Sodani; Tanaji T Talele; Suresh V Ambudkar; Zhe-Sheng Chen; Hai-Ying Wu; Li-Wu Fu
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

2.  Understanding transport through pharmacological barriers--are we there yet?

Authors:  Balázs Sarkadi; Gergely Szakács
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

3.  Modulation of fungal sensitivity to staurosporine by targeting proteins identified by transcriptional profiling.

Authors:  Andreia S Fernandes; A Pedro Gonçalves; Ana Castro; Telma A Lopes; Rui Gardner; N Louise Glass; Arnaldo Videira
Journal:  Fungal Genet Biol       Date:  2011-10-05       Impact factor: 3.495

Review 4.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

5.  Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.

Authors:  Lei Luo; Ye Liang; Xuemei Ding; Xiaocheng Ma; Guiming Zhang; Lijiang Sun
Journal:  Oncol Lett       Date:  2019-06-06       Impact factor: 2.967

6.  Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.

Authors:  Shahrooz Vahedi; Eduardo E Chufan; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2017-07-17       Impact factor: 5.858

7.  Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila.

Authors:  Fahima Mayer; Nasima Mayer; Leslie Chinn; Robert L Pinsonneault; Deanna Kroetz; Roland J Bainton
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

8.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

Authors:  Eran E Bram; Michal Stark; Shachar Raz; Yehuda G Assaraf
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Authors:  Yi-Jun Wang; Rishil J Kathawala; Yun-Kai Zhang; Atish Patel; Priyank Kumar; Suneet Shukla; King Leung Fung; Suresh V Ambudkar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-06-14       Impact factor: 5.858

10.  Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).

Authors:  Durga Kalyani Paturi; Deep Kwatra; Hari Krishna Ananthula; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2009-09-25       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.